All Categories - BioCapital Europe | February 2025

New Amsterdam Pharma

NUA Surgical

NUA Surgical is an award-winning Irish start-up that strives to reduce the risk of maternal complications following cesarean delivery through their patented technology.

Noselab

Cyted

Vesper Bio

Vesper is a clinical stage biotech and world leader in sortilin receptor biology.

Exciva

Tympany Medical

Tympany Medical is innovating at the intersection of mechanics, optics, electronics miniaturisation, and human-centred design to deliver cutting edge products to the surgical endoscope market.

Pharvaris

AMT Medical

AMT is on the eve of disrupting the medieval treatment of open-heart surgery where the chest is still completely split with all the risks of complications and months of recovery. The innovative AMT technology enables cardiac surgeons to perform off-pump heart bypass surgery, enabling minimally invasive closed chest surgery (MIDCAB) and keyhole and robot surgery (TECAB).

FundaMentalPharma

FundaMental Pharma (“FundaMental”) is an innovative CNS company developing an entirely new class of drugs that safely counteract glutamate excitotoxicity for the treatment of a range of neurodegenerative diseases.

Lario Therapeutics

Ceroflo

Ceroflo Limited, based in Galway, Ireland, founded by some of the most respected and recognisable names in stroke treatment, and the Irish MedTech sector, is developing an innovative device for the treatment and prevention of stroke – one of the leading causes of death and disability across the world.

ViCentra

AlzeCure

AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer’s disease and pain – indications for which currently available treatment is very limited.

ImCheck Therapeutics

Altoida

Altoida is a pioneer in developing digital biomarkers of neurological conditions, including Alzheimer’s Disease, using augmented reality and machine learning.

Mirai Medical

At Mirai Medical, we are passionate about developing technology that greatly improves cancer outcomes and enhances patient experiences.

MinervaX

MinervaX is developing a novel innovative vaccine candidate against Group B Streptococcus.

Agomab Therapeutics

Agomab is a biotech company developing novel treatments that aim to preserve and restore organ function in fibrotic diseases.

Artios Pharma

Artios is a leading independent DNA Damage Response company with a strong pipeline of novel cancer therapies in development with first and best in-class potential.